Table 2.
Medical data collected by site investigators
| Baseline characteristics | Total (n = 35) |
|---|---|
| Time since diagnosis, years | |
| Median | 11 |
| Date of first diagnosis, month year | |
| Range | June 1979–August 2015 |
| Keratoconus stage according to Amsler–Krumeich classification, n (%) | |
| Stage 1 | 7 (20.0) |
| Stage 2 | 12 (34.3) |
| Stage 3 | 8 (22.9) |
| Stage 4 | 8 (22.9) |
| Current keratoconus treatment*, n (%) | |
| RGPCL | 9 (25.7) |
| CXL | 9 (25.7) |
| ICRS | 8 (22.9) |
| Corneal transplantation | 9 (25.7) |
| Current symptoms, n (%) | |
| Discomfort in night vision | 16 (45.7) |
| Blurred vision | 15 (42.9) |
| Photophobia | 10 (28.6) |
| Distorted vision | 8 (22.9) |
| Eye irritation (watery eyes) | 8 (22.9) |
| Monocular diplopia or polyopia | 7 (20.0) |
| Other | 5 (14.3) |
| Comorbidities, n (%) | |
| Allergy/allergy to drugs | 6 (17.1) |
| Pulmonology/respiratory system | 3 (8.6) |
| Dermatology | 3 (8.6) |
| Neurology | 2 (5.7) |
| Cardiology/cardiovascular | 2 (5.7) |
| Upper limbs/lower limbs | 1 (2.9) |
| Genitourinary system | 1 (2.9) |
| Endocrinology/metabolism | 1 (2.9) |
| Congenital genetic diseases | 1 (2.9) |
| Other | 2 (5.7) |
*In case of multiple treatments, the last and most invasive was taken: (1) rigid gas permeable contact lenses (RGPCL), (2) corneal cross-linking (CXL), (3) intrastromal corneal ring segments (ICRS) and (4) corneal transplantation. In the case of cross-linking, no other treatments were associated with it